Determining the Safety of CAR T-Cell Therapy for Lymphoma
Phase I Dose-Escalation/Expansion Study of Anti-CD19/CD22 CAR T-Cell Therapy for Relapsed/Refractory Mature B-cell Lymphoma After Prior CD19 CAR T-Cell Failure
This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
調査の概要
状態
詳細な説明
This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
When non-Hodgkin lymphoma returns (relapses) or stops responding to treatment (refractory), standard options like chemotherapy or common targeted drugs can become ineffective. This study evaluates a treatment approach called CAR T-cell therapy. CAR T-cell therapy uses a participant's own immune cells (T cells) to hunt down and fight cancer.
Participants in this study will first have their T cells collected through a process called leukapheresis, where blood is drawn, spun through a machine to filter out T cells, and the remaining blood is returned to the body. In the laboratory, these T cells are modified with a Chimeric Antigen Receptor (CAR) protein, which acts like a targeting system to help the T cells recognize two specific markers on lymphoma cells: Cluster of Differentiation 19 (CD19) and Cluster of Differentiation 22 (CD22). The modified CAR T-cells are then given back to the participant through an intravenous (IV) infusion.
The main goal of this study is to find the safest and most effective dose of anti-CD19/CD22 CAR T-cells without causing unexpected or severe side effects. The study also evaluates how the body reacts to the treatment and measures how well the therapy works at shrinking or eliminating the cancer.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Clinical Trials Intake
- 電話番号:8557028222
- メール:cancerclinicaltrials@bsd.uchicago.edu
研究場所
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- The University of Chicago Medicine Comprehensive Cancer Center
-
コンタクト:
- Clinical Trials Intake
- 電話番号:855-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
主任研究者:
- Alexandra E. Rojek, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
- At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma70
- Measurable disease defined as ≥ 1 measurable nodal lesion (long axis > 1.5 cm and short axis > 1.0 cm) or ≥ 1 measurable extranodal lesion (long axis > 1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI)
- Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
- Total bilirubin ≤ 2.0 mg/dL (or < 3.0 mg/dL for subjects with Gilbert's syndrome or lymphomatous infiltration of the liver)
- Alanine aminotransferase (AST) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN); or ≤ 5 x ULN if known lymphomatous infiltration of the liver
- Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min
- Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) ≥ 40% as assessed by echocardiography, multigated acquisition scan (MUGA), or cardiac MRI
- Baseline oxygen saturation ≥ 92% on room air
- Adequate bone marrow function without growth factor support with short-acting G-CSF within the previous 7 days or long-acting G-CSF within the previous 14 days, and without transfusion support within 7 days prior to apheresis:
- Absolute neutrophil count (ANC) ≥ 1,000/microliter (µL)
- Absolute lymphocyte count (ALC) ≥ 100/microliter (µL)
- Platelets ≥ 50,000/microliter (µL)
- Hemoglobin ≥ 7g/dL
- Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- The presence of any of the following will exclude a subject from study enrollment:
- Presence of acute or extensive chronic graft versus host disease (GVHD).
- Active central nervous system or meningeal involvement by lymphoma. Subjects with untreated brain metastases/central nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced MRI imaging for at least 90 days prior to registration.
- History of another primary malignancy that has not been in remission for at least 2 years. The following are examples of exemptions from the 2-year limit: nonmelanoma skin cancer, definitively treated stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou (PAP) smear, and in situ breast cancer that has been completely resected.
- HIV seropositivity.
- Subjects with uncontrolled intercurrent illness.
- Pregnant or breastfeeding women are excluded from this study because CAR T-cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Subjects of either sex who are not willing to practice birth control from the time of consent and at least 6 months after protocol-directed CAR T-cell infusion are excluded (see Section 9.6 for contraception method). Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR T-cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.
- Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
- Presence of an active and clinically relevant CNS disorder such as epilepsy, generalized seizure disorders, paresis, aphasia, stroke, uncontrolled cerebrovascular disease, cerebellar disease, severe brain injuries, dementia and Parkinson's disease
- History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.
- Patients who have received >1 prior CAR T-cell infusion. Patients treated with multiple CAR T-cell infusions in the context of a prior prospective therapeutic clinical trial will be permitted.
- Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
- History of severe immediate hypersensitivity reaction to tocilizumab, anakinra or any of the agents used in this study
- Major surgery within 28 days prior to start of lymphodepleting chemotherapy or any planned medical/surgical treatment that might interfere with the ability to comply with the study requirements.
- Patients must have a washout period of at least 2 weeks or 5 half-lives, whichever is shorter, since any prior cancer therapy, at the time the patient undergoes apheresis, except as follows:
- Treatment with alemtuzumab or bendamustine within 6 months of apheresis, or treatment with fludarabine, melphalan, or cladribine within 3 months of apheresis
- Allogeneic hematopoietic stem cell transplant within 12 weeks prior to apheresis
- Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 5 days prior to apheresis. Physiologic replacement, topical, and inhaled steroids are permitted.
- Oral targeted agents, including lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed prior to apheresis.
- Experimental agents within 4 weeks of apheresis unless no response or disease progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to apheresis
- Radiation within 6 weeks of apheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion or lesions, if additional non-irradiated PET-positive lesions are present, is allowed up to 2 weeks prior to apheresis.
- Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both cluster of differentiation 19 (CD19) and cluster of differentiation 22 (CD22).
- Prior bispecific T-cell engaging antibody therapy targeting cluster of differentiation 20 (CD20), cluster of differentiation 19 (CD19), or cluster of differentiation 22 (CD22) on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
- CD19-directed CAR T-cell infusion within 12 weeks of planned apheresis.
- Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both CD19 and CD22.
- Prior bispecific T-cell engaging antibody therapy targeting CD20, CD19, or CD22 on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
- CNS prophylaxis (e.g., intrathecal methotrexate): must be stopped at least 1 week prior to apheresis
- Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2 [IL-2]) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to apheresis.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dose-Finding (Dose Escalation) Group
This group is part of the dose-finding phase of the study. The goal of this phase is to find the safest and most effective dose of CAR T-cell therapy with the fewest side effects. Participants in this group will first receive lymphodepleting chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion). After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells. They will receive 1 of 4 dose levels of CAR T-Cells based on when they join the study and side effects to each dose level. Up to 18 participants will be in this group. |
他の名前:
Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).
他の名前:
Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).
他の名前:
|
|
実験的:Dose Expansion Group
This group is part of the dose expansion phase of the study. The goal of this phase is to further test the dose of CAR T-cell therapy that was selected during the dose-finding phase. Participants in this group will first receive chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion). After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells at the selected dose. Up to 36 participants will be in this group. |
他の名前:
Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).
他の名前:
Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safe Dose Level (Recommended Phase 2 Dose)
時間枠:Day 30 after CAR T-cell infusion
|
To find the safest dose of anti-CD19/22 CAR T-cells as assessed by tracking severe side effects (dose-limiting toxicities) during the first month after treatment. |
Day 30 after CAR T-cell infusion
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety Profile of Anti-CD19/CD22 CAR T-cells
時間枠:First day of CAR T-cell infusion (Day 0) through 12 months after infusion
|
To describe the safety profile related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. |
First day of CAR T-cell infusion (Day 0) through 12 months after infusion
|
|
Severity of Toxicities Related to Treatment with Anti-CD19/CD22 CAR T-cells
時間枠:First day of CAR T-Cell infusion (Day 0) through 12 months after infusion
|
To record the severity of toxicities (side effects) related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. |
First day of CAR T-Cell infusion (Day 0) through 12 months after infusion
|
|
Percentage of Participants with Overall Response Rate
時間枠:Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
|
The percentage of participants whose cancer shrinks or completely disappears (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments). |
Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
|
|
Percentage of Participants with Complete Response Rate
時間枠:Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
|
The percentage of participants who show a complete disappearance of all signs of cancer (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments). |
Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Alexandra E. Rojek, MD、University of Chicago
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 免疫系疾患
- 組織型別の新生物
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫
- ヘミックおよびリンパ疾患
- リンパ腫、B細胞
- リンパ腫、非ホジキン
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 調査手法
- 治療
- 炭化水素
- ホスホルアミドマスタード
- 窒素マスタード化合物
- マスタード化合物
- 炭化水素、ハロゲン化
- ホスホラミド
- 有機リン化合物
- 受容体、細胞表面
- 膜タンパク質
- 生物療法
- 免疫学的技術
- 免疫調節
- 養子縁組
- 予防接種、パッシブ
- 免疫
- 免疫療法
- 受容体、免疫学的
- 受容体、人工
- 受容体、抗原、T細胞
- 受容体、抗原
- 受容体、細胞質および核
- シクロホスファミド
- フルダラビン
- フルダラビンリン酸
- 免疫療法、養子縁組
- 受容体、キメラ抗原
その他の研究ID番号
- IRB26-1043
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。